Ethos Technologies Corp. Stock Price, News & Analysis

aTyr Pharma has reached a significant milestone with a $10 million payment from Kyorin Pharmaceutical after the first patient was dosed in Japan for the EFZO-FIT™ Phase 3 study. This pivotal trial evaluates the safety and efficacy of efzofitimod in treating pulmonary sarcoidosis. The $20 million paid to date represents the company’s progression under their collaboration agreement, with potential for up to $155 million more in future milestones. Efzofitimod, an immunomodulator with FDA Fast Track and orphan drug designations, is aimed at patients with limited treatment options, marking a pivotal opportunity for aTyr in the ILD therapeutic space.

aTyr Pharma (Nasdaq: LIFE) announced it will present data on efzofitimod's mechanism of action (MOA) and exposure-efficacy at the ATS 2023 International Conference, May 19-24, in Washington, DC. The presentations highlight advancements in understanding efzofitimod’s clinical benefits for pulmonary sarcoidosis, a serious interstitial lung disease. According to CEO Sanjay S. Shukla, the studies support clinical proof-of-concept, showcasing efzofitimod's modulation of myeloid cells. The presentations include a mini symposium on efzofitimod’s immunological impact and a thematic poster session on exposure-efficacy analysis.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced that the European Patent Office has issued a Notice of Allowance for a patent covering the use of efzofitimod in combination with pirfenidone, an anti-fibrotic drug approved for treating idiopathic pulmonary fibrosis (IPF). This patent strengthens aTyr's position, supporting its ongoing clinical development of efzofitimod, aimed at reducing inflammation and fibrosis in the lungs. The patent grants aTyr over 220 issued or allowed patents, highlighting its leadership in developing first-in-class medicines from its tRNA synthetase platform. The patent is expected to be issued soon.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced the European Commission’s grant of orphan drug designation for efzofitimod, its lead candidate targeting pulmonary sarcoidosis. This designation recognizes the unmet medical need for the estimated 150,000 patients in the EU suffering from this chronic disease. Efzofitimod is a first-in-class immunomodulator designed to improve lung function and quality of life, currently undergoing a pivotal Phase 3 study. This status provides benefits like 10 years of market exclusivity and reduced fees. The drug has also received orphan and Fast Track designations from the FDA in the US.

aTyr Pharma, Inc. (Nasdaq: LIFE) has announced the identification of LTBP1 as a target through its tRNA synthetase platform in collaboration with Dualsystems Biotech AG. LTBP1 serves as a key regulator of transforming growth factor beta (TGF-β), involved in fibrotic diseases. The company plans to present further findings related to LTBP1 at an upcoming scientific conference. This discovery is aimed at advancing the development of new therapeutic candidates targeting immune regulation and fibrosis.

aTyr Pharma (Nasdaq: LIFE) announced the granting of stock options to four employees, totaling 13,200 shares with an exercise price of $2.38 per share. These options are part of the 2022 Inducement Plan and are designed to incentivize new hires. The options vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the next three years. aTyr focuses on developing first-in-class medicines from its tRNA synthetase platform, with a key product candidate being efzofitimod, aimed at treating fibrotic lung disease.

aTyr Pharma, Inc. (NASDAQ: LIFE) announced the first patient dosing in the Phase 3 EFZO-FIT™ study for pulmonary sarcoidosis, a significant milestone for the company. The study aims to enroll 264 subjects across multiple centers. The company ended Q3 2022 with $79.6 million in cash and equivalents. To prioritize resources, aTyr will focus on the efzofitimod program and has postponed the Phase 1 study of ATYR2810. The FDA has granted Fast Track designation for efzofitimod, enhancing its development prospects. A conference call is scheduled for November 10, 2022, to discuss results and updates.

aTyr Pharma (Nasdaq: LIFE) has announced that President and CEO Sanjay S. Shukla, M.D., M.S., will present at three investor conferences in November and December 2022. The conferences include the Jefferies London Healthcare Conference on November 15, Piper Sandler Annual Healthcare Conference on November 29, and Evercore ISI HealthCONx Conference on December 1. Webcasts of the presentations will be available on the company's website, with replays accessible for 90 days post-event. aTyr focuses on developing first-in-class medicines using its tRNA synthetase platform.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced positive results from its Phase 1b/2a trial of efzofitimod for pulmonary sarcoidosis, published in CHEST. The study showed dose-dependent improvements in lung function and symptom relief while reducing steroid use. Efzofitimod demonstrated safety and tolerability across all doses. A pivotal Phase 3 study, EFZO-FIT™, is currently enrolling patients, aiming to establish efzofitimod as the first disease-modifying therapy for this condition, benefiting a significant population of nearly 200,000 Americans.